Risk factors for irAEs’ recurrence after ICI retreatment include an immunological background (i.e., autoimmune disease history or autoantibodies’ positivity), anti-CTLA-4 regimen, and younger age. The gene discussed is CTLA4; the disease is autoimmune disease.